1: Schettino CJ, Kamer EL, Noz ME, et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR. 2004; 183:519-524.

Patient management should not be based on ProstaScint® scan results without appropriate confirmatory studies since in the pivotal trials, there was a high rate of false positive and false negative image interpretations. ProstaScint images should be interpreted only by physicians who have had specific training in ProstaScint image interpretation. Medications for the treatment of hypersensitivity reactions should be available during administration of this agent.

Copyright ©2008 Cytogen, Inc. All rights reserved